



NEWS RELEASE

CareDx Drives Personalized Medicine in Transplantation at CEOT

2019-02-20

AlloSure highlighted at Cutting Edge in Transplantation conference in multiple sessions
BRISBANE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that CareDx will lead a mainstage presence at the 2019 Cutting Edge of Transplantation (CEOT) in Phoenix, Arizona, from February 21 – 23.

The 2019 theme at CEOT is No Size Fits All: Uncovering the Potential of Personalized Transplantation. AlloSure is prominently featured in the main program. Dr. Roy Bloom, Medical Director, Kidney/Pancreas Transplant Program at University of Pennsylvania and the lead author on AlloSure's clinical validation publication, will be presenting "The Force is in the cfDNA" from the main stage on the opening day. Dr. Kiran Khush, transplant cardiologist at Stanford and a principal investigator for the CareDx sponsored HeartCare registry SHORE, will be presenting "Donor Derived Cell Free DNA - Has the Answer Been There All Along?"

"The CEOT program highlights CareDx's close collaboration with a very large number of the clinical leaders of advances in transplantation. I am glad to see that AlloSure and the clinicians that CareDx has partnered with in the development of AlloSure are prominently featured across the kidney, heart, and lung program tracks," said Jim Yee, Chief Medical Officer, CareDx. "The theme of Personalized Transplantation shows the impact we are having in the field, driven by our dedication to transplant patient outcomes."

CareDx is hosting a lunch symposium on Personalizing Allograft Health Surveillance with AlloSure at CEOT on Friday, February 22. "The AlloSure results have had a very positive impact on our patients and practice. I am excited to share my center's experience with the transplant community," said Dr. Tarek Alhamad, M.D., Medical Director of

Transplant Nephrology at Barnes Jewish Medical Center. The symposium's agenda is as follows:

Case studies highlighting clinical utility of AlloSure

- Tarek Alhamad, M.D., Medical Director of Transplant Nephrology, at Barnes Jewish Medical Center
- Stanley Jordan, M.D., Director of the Nephrology Division, Ceders Sinai Comprehensive Transplant Center

Panel discussion on AlloSure use in management of lung, heart, and pancreas transplant patients

- Kiran Khush, M.D., Associate Professor of Cardiovascular Medicine, Stanford University Medical Center.
- Mark Nicolls, M.D., Pulmonologist, Stanford University Medical Center
- Jon A. Kobashigawa, M.D., Director of the Heart Transplant Program of Cedars-Sinai

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements, including statements regarding the Company's partnership with the Cedars-Sinai Comprehensive Transplant Center and Cedars-Sinai's use of AlloSure in connection with one of its studies. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed by CareDx with the SEC on March 22, 2018 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx's actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King

Chief Commercial Officer

415-287-2393

sking@caresdx.com

Investor Relations

David Clair

Integrated Corporate Relations, Inc.

646-277-1266

david.clair@icrinc.com

Source: CareDx, Inc.